Serum levels of high sensitivity C-reactive protein in drug-naïve first-episode psychosis and acute exacerbation of schizophrenia
Abdullah Bolu 1, Mehmet Sinan Aydın 1*, Abdullah Akgün 1, Ali Coşkun 2, Beyazıt Garip 1, Taner Öznur 1, Cemil Çelik 1, Özcan Uzun 1
1Health Sciences University, Gulhane Medical Faculty, Department of Psychiatry, 2Health Sciences University, Gulhane Medical Faculty
Received: May 21, 2018; Revised: July 16, 2018; Accepted: August 16, 2018; Published online: August 16, 2018.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Objective: Findings about inflammatory processes in schizophrenia are increasing day by day. Inflammatory processes in schizophrenia are associated with both its etiology and clinical symptoms. Serum high sensitivity c-reactive protein (hsCRP) is also one of these inflammatory processes. Particularly, it is thought to be closely related to clinical findings of patients with schizophrenia.
Methods: In this study, the relationship between clinical findings of hsCRP levels of patients with drug naive first episode psychosis (FEP) and patients with schizophrenia (SZ) in acute exacerbation phase is investigated. 48 patients with FEP, 74 patients with SZ in acute exacerbation phase and 54 HC volunteers are included in the study.
Results: The most substantial finding in the study is that there is a positive correlation between hsCRP levels and severity of positive symptoms of both patient groups, with FEP and with SZ. The second most substantial finding is there is no significant difference between patients with FEP and SZ, in terms of hsCRP.
Conclusion: This finding is supportive of close relation between inflammatory processes and clinical findings of patient with schizophrenia.
Keywords: high sensitivity, c-reactive protein, drug-naïve, first-episode, psychosis, acute exacerbation, schizophrenia, inflammatory, CRP, hs CRP, clinical findings, proinflammatory